We elected to recruit patients with and without T2D to enhance recruitment rates and broaden the safety data in liraglutide in NASH, but under the provision that patients with diabetes must have moderate glycaemic control (HbA1c <9%) on diet ± oral hypoglycaemic medications (with the exception of TZDs and other potential confounders, ie, GLP-1 based therapy) prior to trial entry. This evidence concerns the gene GLP1R and metabolic dysfunction-associated steatohepatitis.